Can Farxiga Be Taken With Insulin?
Yes, Farxiga (dapagliflozin) can be taken with insulin. The FDA approves this combination for adults with type 2 diabetes to improve glycemic control when diet, exercise, and other therapies alone are inadequate. Farxiga, an SGLT2 inhibitor, reduces blood sugar by blocking glucose reabsorption in the kidneys, complementing insulin's action without direct interaction issues.[1][2]
How Does the Combination Work?
Farxiga lowers blood glucose independently of insulin by promoting urinary glucose excretion. When added to insulin or insulin regimens (like basal or prandial insulin), it enhances A1C reduction—clinical trials show an additional 0.5-1% drop over insulin alone. Dosing starts at 5 mg daily for Farxiga, adjustable to 10 mg, while insulin doses may need reduction by 10-20% at initiation to avoid hypoglycemia.[1][3]
What Do Clinical Trials Show?
In pivotal studies like DECLARE-TIMI 58, Farxiga plus insulin (in ~20% of participants) reduced cardiovascular events and hospitalization for heart failure without increasing severe hypoglycemia rates compared to placebo. A1C improvements held across insulin users, with weight loss as a bonus (2-3 kg average).[2][4]
Common Side Effects With Insulin
Hypoglycemia risk rises, especially with intensive insulin control—monitor closely and adjust doses. Other effects include genital yeast infections (5-10% incidence), dehydration, and ketoacidosis (rare, 0.1%). No contraindications block the combo, but caution applies in renal impairment (eGFR <45 mL/min).[1][2]
Who Should Avoid This Combination?
Not for type 1 diabetes (increases ketoacidosis risk, per black box warning). Avoid in dialysis patients or severe kidney disease. Pregnancy category C; use alternatives in lactation.[1]
Dosage and Monitoring Tips
Take Farxiga once daily, morning preferred, with or without food. Check blood sugar frequently at start; aim for eGFR >45 initially. Annual kidney function tests required.[3]
[1]: FDA Farxiga Label
[2]: Farxiga Prescribing Information
[3]: ADA Standards of Care 2023
[4]: NEJM DECLARE-TIMI 58 Trial